Please login to the form below

Not currently logged in
Email:
Password:

cell and gene therapy

This page shows the latest cell and gene therapy news and features for those working in and with pharma, biotech and healthcare.

Bayer strengthens cell and gene therapy focus with new platform

Bayer strengthens cell and gene therapy focus with new platform

The new cell and gene therapy platform will house both AskBio and another of Bayer’s recently acquired firms, BlueRock Therapeutics, under one roof. ... The company also said that it has a ‘vibrant’ cell and gene therapy pipeline with five advanced

Latest news

  • Bayer pays an initial $2bn for gene therapy firm AskBio Bayer pays an initial $2bn for gene therapy firm AskBio

    Acquisition will expand Bayers’s pipeline with preclinical/clinical candidates. Bayer has announced its acquisition of Asklepios BioPharmaceutical (AskBio) to bolster its presence in cell and gene therapy, paying up to ... Germany-based Bayer will pay

  • NICE plans to widen the net for data it uses in guidance NICE plans to widen the net for data it uses in guidance

    guidance and allow existing recommendations to be updated more quickly, said the agency. ... That update is intended to take into account developments such as personalised medicine, digitisation of health and use of cell and gene therapy.

  • Novartis defends Zolgensma as FDA investigates ‘data manipulation’ Novartis defends Zolgensma as FDA investigates ‘data manipulation’

    Novartis acquired the gene therapy specialist AveXis in April last year and Zolgensma had been subsequently developed by them. ... There had already been concerns over how commercially sustainable the field of cell and gene therapy is, with Zolgensma’s

  • NICE unveils long-awaited review of methodologies NICE unveils long-awaited review of methodologies

    He added: “NICE is undertaking this review at a time of unprecedented change in the healthcare system, where developments such as personalised medicine, digitalisation of health, and use of cell and ... gene therapy, mean products are becoming ever

  • FDA will maintain the pace, vows Woodcock, but warns of skills gap FDA will maintain the pace, vows Woodcock, but warns of skills gap

    a potential flood of new cell and gene therapy products. ... Also eyecatching were Woodcock’s comments on two high profile FDA approvals of spinal muscular atrophy (SMA) treatments, Biogen’s Spinraza and Novartis’ gene therapy Zolgensma.

More from news
Approximately 41 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream

    Often lumped together as terms, the key difference between cell therapy and gene therapy is that the former utilises cells from a donor or the patient themselves to treat a disease ... The cell therapy, gene therapy and tissue engineering sector raised $2

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    Takeda’s Asit Parikh talks about a game changer for IBD patients and the company’s long-term strategy for gene and cell therapy. ... Takeda’s strategy is to develop GI products that address the highest unmet needs, which includes projects across

  • Delivering the promise of regenerative medicine Delivering the promise of regenerative medicine

    The Cell and Gene Therapy Catapult is also continuing to work to bridge the gap between ‘translational’ research and commercialisation. ... to cell and tissue requirements.

  • Assessing the risks in annuity pricing models Assessing the risks in annuity pricing models

    The number of companies targeting the development of new cell and gene therapies has risen dramatically in recent years. . ... Despite the challenges, some cell and gene therapy companies have already launched products based on annuity pricing models.

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    13. SORAYA BEKKALI. Gene therapy pioneer. Cell and gene therapy is definitely the most exciting development in biopharma research, promising breakthroughs and even cures for previously untreatable diseases. ... Eye diseases are at the forefront of the

More from intelligence
Approximately 2 fully matching, plus 13 partially matching documents found.

Latest appointments

  • Health comms agency emotive hires new cell and gene therapy leader Health comms agency emotive hires new cell and gene therapy leader

    Dr Germano Ferrari. His most recent role was as a programme manager at the UK’s Cell and Gene Therapy Catapult where he helped develop commercialisation pathways for several pre-clinical ... Dr Ferrari said “We have now reached a turning point where

  • Weekly industry appointments Weekly industry appointments

    GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    He said: “Now is an exciting time to be joining Orchard as the cell and gene therapy field is advancing successfully. ... The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and

  • Avita Medical appoints CEO Avita Medical appoints CEO

    chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... and Genetic Therapy Inc. Lou Panaccio, chairman of Avita, said: “Mike’s expertise across the value chain in cell

  • apceth Biopharma appoints Dusan Kosijer as CFO apceth Biopharma appoints Dusan Kosijer as CFO

    He said: “I am excited and honoured to be able to contribute to the company that operates successfully for almost 10 years in the fast-moving field of cell and gene ... successful track record as one of the leading CDMOs for complex cell and gene

More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics